التفاصيل البيبلوغرافية
| العنوان: |
Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. |
| المؤلفون: |
Wijs, L.E.M., Nguyen, N.T., Kunkeler, A.C.M., Nijsten, T., Damman, J., Hijnen, D.J. |
| المصدر: |
British Journal of Dermatology; Oct2020, Vol. 183 Issue 4, p745-749, 5p |
| مصطلحات موضوعية: |
ATOPIC dermatitis, ERYTHEMA, T cells, NECK, PLASMA cells, PLASMACYTOMA, ERYTHEMA multiforme |
| مستخلص: |
Summary: Dupilumab is the first biologic registered for the treatment of atopic dermatitis (AD). We report on seven patients with AD presenting with a paradoxical head and neck erythema that appeared 10–39 weeks after the start of dupilumab treatment. The patients presented with a relatively sharply demarcated, patchy erythema in the head and neck area that showed no or less scaling compared with their usual eczema. Only one patient experienced symptoms of itch and burning, although this was notably different from his pre‐existent facial AD. Except for a notable 'red face', eczema on other body parts had greatly improved in six of the seven patients, with a mean numerical rating scale for treatment satisfaction of 9 out of 10 at the time of biopsy. Treatment of the erythema with topical and systemic drugs was unsuccessful. Despite the presence of this erythema, none of our patients discontinued dupilumab treatment. Lesional skin biopsies showed an increased number of ectatic capillaries, and a perivascular lymphohistiocytic infiltration in all patients. In addition, epidermal hyperplasia with elongation of the rete ridges was observed in four patients, resembling a psoriasiform dermatitis. Additional immunohistochemical stainings revealed increased numbers of plasma cells, histiocytes and T lymphocytes. Interestingly, spongiosis was largely absent in all biopsies. We report on patients with AD treated with dupilumab developing a paradoxical erythema in a head and neck distribution. Both clinically and histopathologically we found a heterogeneous response, which was most suggestive of a drug‐induced skin reaction. What's already known about this topic? Dupilumab has proven to be an efficacious and effective treatment for atopic dermatitis with an acceptable safety profile.The most frequently observed side‐effects in patients with atopic dermatitis treated with dupilumab are conjunctivitis, herpes infections and injection‐site reactions. What does this study add? For the first time, we report on patients with atopic dermatitis treated with dupilumab who developed a paradoxical, mainly asymptomatic erythema in a head and neck distribution.Histological examination of skin biopsies revealed a psoriasiform reaction pattern suggestive of a drug‐induced skin reaction. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Dermatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder